Table 1.
Clinical course of chronic hepatitis B virus infection
| September 2015 | May 2016 | June 2017 | November 2018 | June 2019 | September 2019 | |
| Start of NUC-therapy | Acute HAV-superinfection | Clearance of HBs antigen | Clearance of HBs antigen | |||
| HBs-antigen QL | Positive | Low | Low | Low | Negative | Negative |
| HBs antigen (IU/mL) | 1 986.0 | 1 956.0 | 64.12 | 0.04 | 0.00 | 0.00 |
| anti-HBs QL | Negative | Negative | Negative | Negative | Positive | Positive |
| anti-HBs (IU/mL) | Negative | Negative | Negative | Negative | 159.21 | 380.29 |
| anti-HBc IgM QL | Positive | Negative | Negative | Negative | Negative | Negative |
| HBe-antigen QL | Positive | Positive | Negative | Negative | Negative | Negative |
| anti-HBe | 4371.0 | 2.94 | 1.37 | Negative | Negative | Negative |
| HBV-PCR QL | Positive | Low | Low | Positive | Negative | Negative |
| HBV-PCR (IU/mL) | 380000 | 20 | 150 | < 10 | BDL | BDL |
| GOT (U/L) | 78 | 25 | 19 | 1334 | 14 | 13 |
| GPT (U/L) | 148 | 40 | 25 | 3387 | 20 | 20 |
Glutamic oxalacetic transaminase and glutamate pyruvate transaminase (Reference: 10-50 U/L). BDL: Below detection limit; HAV: Hepatitis A virus; GOT: Glutamic oxalacetic transaminase; GPT: Glutamate pyruvate transaminase; HBs: Hepatitis B surface; HBV: Hepatitis B virus; IgM: Immunoglobulin M; PCR: Polymerase chain reaction.